To improve both the breadth and durability of tumour recognition, preclinical studies are evaluating dual-target CAR-NK constructs (like CD19/NKG2D) and modular antigen-sensing circuits [121, 271, 345–348, 350–352]. This evidence concerns the gene CD19 and neoplasm.